SU552744A1 - Method of preparing soluble pertussoid immunologic adjuvant - Google Patents

Method of preparing soluble pertussoid immunologic adjuvant

Info

Publication number
SU552744A1
SU552744A1 SU7502303724A SU2303724A SU552744A1 SU 552744 A1 SU552744 A1 SU 552744A1 SU 7502303724 A SU7502303724 A SU 7502303724A SU 2303724 A SU2303724 A SU 2303724A SU 552744 A1 SU552744 A1 SU 552744A1
Authority
SU
USSR - Soviet Union
Prior art keywords
pertussoid
immunologic adjuvant
preparing soluble
fractionation
carried out
Prior art date
Application number
SU7502303724A
Other languages
Russian (ru)
Inventor
А.Н. Мац
А.Л. Табачник
Н.П. Перепечкина
В.Г. Лиходед
Original Assignee
Московский Научно-Исследовательский Институт Вакцин И Сывороток Им. И.И. Мечникова Министерства Здравоохранения Ссср
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Московский Научно-Исследовательский Институт Вакцин И Сывороток Им. И.И. Мечникова Министерства Здравоохранения Ссср filed Critical Московский Научно-Исследовательский Институт Вакцин И Сывороток Им. И.И. Мечникова Министерства Здравоохранения Ссср
Priority to SU7502303724A priority Critical patent/SU552744A1/en
Application granted granted Critical
Publication of SU552744A1 publication Critical patent/SU552744A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

-:; ..- - ,; ,---- . ф-Ч- .- :; ..- -,; , ---- f-h-

г« i - . Vr «i -. V

552744552744

фера в надмембранную Фракцию подают дистиллированную воду, после чего надмембранную фракцию концентрируют, прогревают при 55-65°С в течение 2030 мин и лиофилизируют.the ferra is fed to the supramembrane fraction and distilled water is added, after which the supermembrane fraction is concentrated, heated at 55-65 ° C for 2030 minutes, and lyophilized.

Относительна  адъювантна .активность препарата,полученного предлагаемым способом, в 5 раз выше корпускул рной коклюшной вакцины. Дл  достижени  равного иммуноадъювантного эффекта предлагаемого препарата доза может быть снижена в 5 раз. Токсичность , .гистамин-сенсибилиэирующа  и реагин-стимулирующа  активности снижены в Юг50 раз.The relative adjuvant activity of the preparation obtained by the proposed method is 5 times higher than the particulate pertussis vaccine. To achieve an equal immunoadjuvant effect of the proposed drug, the dose can be reduced by 5 times. Toxicity, histamine-sensitizing and reagin-stimulating activities are reduced by 50 times.

Claims (1)

Формула изобретени Invention Formula Способ получени  растворимого коклюшного иммуноадъюванта путем дезинтеграции коклюшных бактерий с последующим фракционированием, о т л и чающийс   тем, что, с целью снижени  токсичности, гистамин-сенсибилизирующей и реагин-стимулирующей активности , фракционирование осуществл ют сульфатом стрептомицина или дигидрострептомицина , полученный осадок раствор ют в высокомолекул рном натрийфосфатном буфере, выдел ют вещества с молекул рным весом выше и прогревают Их при Бб-бБ С в течение 2030 мин.The method of obtaining soluble pertussis immunoadjuvant by the disintegration of pertussis bacteria, followed by fractionation, is carried out by the fact that, in order to reduce toxicity, histamine-sensitizing and reagin-stimulating activity, fractionation is carried out with streptomycin sulfate or dihydro Streptomycin, a drug. sodium phosphate buffer, substances with a molecular weight are higher and are heated by them at BB-BB for 2030 minutes.
SU7502303724A 1975-12-25 1975-12-25 Method of preparing soluble pertussoid immunologic adjuvant SU552744A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU7502303724A SU552744A1 (en) 1975-12-25 1975-12-25 Method of preparing soluble pertussoid immunologic adjuvant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU7502303724A SU552744A1 (en) 1975-12-25 1975-12-25 Method of preparing soluble pertussoid immunologic adjuvant

Publications (1)

Publication Number Publication Date
SU552744A1 true SU552744A1 (en) 1977-11-05

Family

ID=20642080

Family Applications (1)

Application Number Title Priority Date Filing Date
SU7502303724A SU552744A1 (en) 1975-12-25 1975-12-25 Method of preparing soluble pertussoid immunologic adjuvant

Country Status (1)

Country Link
SU (1) SU552744A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4726947A (en) * 1978-03-10 1988-02-23 Matsui Toatsu Chemicals, Inc. Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same
EA021618B1 (en) * 2011-07-19 2015-07-30 Игорь Закванович Зайцев Adjuvant-free corpuscular vaccine and method for producing same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4726947A (en) * 1978-03-10 1988-02-23 Matsui Toatsu Chemicals, Inc. Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same
EA021618B1 (en) * 2011-07-19 2015-07-30 Игорь Закванович Зайцев Adjuvant-free corpuscular vaccine and method for producing same

Similar Documents

Publication Publication Date Title
Dennert et al. Antitumor Polysaccharide Lentinan—AT Cell Adjuvant
US5108745B1 (en) Tuberculosis and legionellosis vaccines and methods for their production
JPS5461112A (en) Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component
YU159991A (en) PROCESS FOR OBTAINING IN WATER SOLUTIONAL ANALOGUES OF CAMPTOTECIN AND INTERMEDIARS FOR THEIR PRODUCTION AS WELL AS COMPOUNDS OBTAINED BY THIS PROCESS
ATE271063T1 (en) PURINE-L-NUCLEOSIDES, THEIR ANALOGUES AND USES
ES2084579T3 (en) USE OF BUSPIRONE IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOL ABUSE.
ES466434A1 (en) Hydrophilic copolymers, their preparation and their use in separation techniques
HUT35521A (en) Process for preparing a pharmaceutical composition containing a purified, detixicated endotoxine and a pyridine soluble extract of a microorganism
BE822929A (en) PHARMACEUTICAL PREPARATIONS INTENDED TO INFLUENCE THE BINDING AND ELIMINATION OF SALTS WITH LITTLE SOLUBLE OF CALCIUM
EP0308197A3 (en) Method for stimulating the immune system
SU552744A1 (en) Method of preparing soluble pertussoid immunologic adjuvant
ES469225A1 (en) Potentiated acellular vaccines
ES522637A0 (en) PROCEDURE FOR THE PREPARATION OF NEW SUBSTANCES WS 6049.
IT1106073B (en) PROCEDURE FOR THE PRODUCTION OF POLYACCARDS BY EXTRACTION FROM THE MICROBIAL BODIES OF THE HAEMOPHILUS IN FLUENCE AND PRODUCT OBTAINED AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AS AN ACTIVE INGREDIENT
IE37742L (en) Therapeutic conjugate oral preparation
ES536055A0 (en) A PROCEDURE FOR THE PRODUCTION OF A COVALENTLY LINKED HEPARIN-ANTITHROMBINE-III COMPLEX
ATA379182A (en) METHOD FOR PRODUCING PRESSURES WITH RETARDED ACTIVE SUBSTANCE RELEASE
DK527186D0 (en) SOURCE CHODILATING PHARMACEUTICAL PREPARATION
ES476703A1 (en) Heterovaccine against the trichomonas syndrome, and process for its preparation
JPS57193415A (en) Preparation of antitumor substance
GB1495940A (en) Anti-cancer active whey fraction
AU4386772A (en) Improvements in or relating to novel compounds for the treatment of excess lipidic and cellulitic stresses, and process for preparing said compounds
BE842814A (en) ANTIGENIC COMPOSITIONS, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS VACCINES
BE778653Q (en) NEW DI- AND TRIHALOGENOPYRAZOLES SUBSTITUTES, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS HERBICIDES
EP0161384A3 (en) Human endogenous cancer regulatory factors, method of preparing the same, and pharmaceutical compositions containing the same